argenx raises $1.1 billion in gross proceeds in a global offering
July 18, 2023 21:30 ET
|
argenx SE
Regulated information — Inside information July 18, 2023, 9:20 PM ET July 19, 2023, 3:20 AM CET Amsterdam, the Netherlands — argenx SE (Euronext & Nasdaq: ARGX), a global immunology...
argenx announces launch of proposed global offering
July 17, 2023 16:01 ET
|
argenx SE
Regulated information — Inside information argenx announces launch of proposed global offering July 17, 2023 Amsterdam, the Netherlands — argenx SE (Euronext & Nasdaq: ARGX), a global...
argenx Reports Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy
July 17, 2023 01:00 ET
|
argenx SE
Study met primary endpoint (p=0.000039); VYVGART® Hytrulo demonstrated 61% reduction (HR: 0.39 95% CI: 0.25; 0.61) in risk of relapse versus placebo IgG autoantibodies shown to play significant role...
argenx and Zai Lab Announce Approval of VYVGART® (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China
June 30, 2023 09:39 ET
|
argenx SE
First-and-only approved FcRn antagonist for gMG patients by NMPA68% of anti-AChR antibody positive gMG patients treated with VYVGART were responders (n=44/65) on the Myasthenia Gravis Activities of...
argenx Announces U.S. Food and Drug Administration Approval of VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Generalized Myasthenia Gravis
June 20, 2023 18:12 ET
|
argenx SE
VYVGART® Hytrulo is first FDA-approved subcutaneous (SC) injectable for generalized myasthenia gravis (gMG) With this approval, argenx broadens innovative gMG product offering and demonstrates...
argenx Initiates Second Cohort of Phase 2 ARDA Study of Empasiprubart in Multifocal Motor Neuropathy
June 20, 2023 01:00 ET
|
argenx SE
Independent Data Monitoring Committee recommended study continuation based on the favorable safety profile observed in the first dose cohortEarly efficacy signals support proof-of-concept of...
argenx to Present at Upcoming Investor Conferences
May 31, 2023 01:00 ET
|
argenx SE
May 31, 2023Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today...
argenx Reports First Quarter 2023 Financial Results and Provides Business Update
May 04, 2023 01:00 ET
|
argenx SE
$218 million in first quarter VYVGART® (efgartigimod alfa-fcab) global net product sales VYVGART received marketing authorization in Israel through partnership with Medison88 events achieved in...
argenx announces results of Annual General Meeting of Shareholders
May 03, 2023 16:01 ET
|
argenx SE
May 3, 2023 Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases,...
argenx to Present at BofA Securities 2023 Health Care Conference
May 02, 2023 01:00 ET
|
argenx SE
May 2, 2023Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today...